Spatial Mapping of Proteomic and Transcriptional Signatures in Kidney Disease

肾脏疾病蛋白质组和转录特征的空间图谱

• 批准号: 10701891
• 负责人: WEN-YUAN E HSIEH
• 金额: $ 55.59万
• 依托单位: UNIVERSITY OF COLORADO DENVER
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-09-15 至 2027-06-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10701891
• 关键词: Acute; Acute Renal Failure with Renal Papillary Necrosis; Albuminuria; Anatomy; Atlases; Award; Bioinformatics; Biological; Biological Assay; Biological Sciences; Biopsy; Biopsy Specimen; Cancer Biology; Cells; Chronic Kidney Failure; Clinical Data; Colorado; Complement; Creatinine; Development; Diagnosis; Disease; Etiology; Expression Profiling; Funding; Gene Expression; Gene Expression Profile; Gene Expression Profiling; Genetic Complementation Test; Genetic Transcription; Goals; Human; Immune; Immunologist; Immunology; Immunotherapy; Injury; Interdisciplinary Study; Kidney; Kidney Diseases; Location; Maps; Medical; Methods; Molecular; Molecular Profiling; Morbidity - disease rate; Morphology; Multiplexed Ion Beam Imaging; Pathologic Processes; Pathologist; Pathway interactions; Patients; Pattern; Phenotype; Process; Proteins; Proteomics; Public Health; RNA; Renal function; Research; Resolution; Resources; Serum; Site; Standardization; Structure; Supportive care; Systems Biology; Technology; Testing; Therapeutic; Tissue atlas; Tissues; Translating; Universities; Widespread Disease; analytical method; anticancer research; candidate marker; cell type; experimental study; hemodynamics; high dimensionality; improved; injury and repair; innovation; insight; kidney biopsy; medical schools; mortality; multidimensional data; multiple omics; novel; novel diagnostics; novel therapeutic intervention; novel therapeutics; precision medicine; protein expression; proteomic signature; renal damage; therapeutic target; tool; transcriptome; transcriptomics; tumor

AKI and CKD are highly prevalent diseases that are associated with significant morbidity and mortality. Unfortunately, there are not currently any specific treatments for either of these conditions. Both diseases are caused by a range of underlying diseases and processes. AKI, for example, can result from hemodynamic, toxic, infectious, and immune insults to the kidney. In both AKI and CKD, the diagnosis is based on changes in the serum creatinine and albuminuria, but these tests do not discriminate among the various etiologies of injury. Thus, beyond detecting a reduction in kidney function, clinicians typically have little information regarding the underlying pathologic process. Better understanding of the cellular and molecular patterns in the kidneys of patients with AKI and CKD will provide key insights into these diseases and will lead to new diagnostic and therapeutic approaches. In recent years, multi-omics analyses have had a major impact on our understanding of several fields, such as cancer biology, and have supported the identification and development of new treatments. These same technologies could transform our understanding of AKI and CKD, particularly when spatial resolution is complemented with proteomic and transcriptomic cellular analyses. Although kidney biopsies are not usually performed in patients with AKI and CKD, biopsy samples obtained through the Kidney Precision Medicine Project (KPMP) offer a valuable opportunity to analyze kidney tissue using state-of-the-art high-dimensional multi-omic platforms. We propose to utilize complementary spatial protein and RNA technologies to generate comprehensive tissue atlases for AKI and CKD. We will pursue the following specific aims: Aim 1. Generate a kidney cellular map via phenotypic and functional protein expression profiling. We will analyze biopsies using Multiplexed Ion Beam Imaging (MIBI), which detects 40+ protein targets at single-cell resolution (250 nm) with tissue-specific spatial information. Aim 2. Generate a kidney morphological map via phenotypic and functional gene expression profiling. We will analyze biopsies using Visium Spatial Transcriptomics (ST), which provides the whole transcriptome with morphological context. Aim 3. Generate an integrated cellular and molecular protein and gene expression kidney atlas. We will apply statistical and bioinformatic approaches to integrate the results from Aims 1 and 2 to create a composite map of the cellular protein and transcriptional expression profiles in the kidney. To accomplish these goals, we have assembled a multidisciplinary research team that includes nephrologists, renal pathologists, immunologists, and experts on multi-omics systems biology analyses. The proposed experiments are expected to reveal subsets of AKI and CKD patients based on the patterns of cells and molecular pathways present in the kidney, and to support identification of novel candidate biomarkers and therapeutic targets.

AKI和CKD是高度流行的疾病，与显着的发病率和死亡率相关。 不幸的是，目前尚无针对这两种情况的任何特定治疗方法。两种疾病 是由一系列潜在的疾病和过程引起的。例如，aki可以由 对肾脏的血液动力学，有毒，传染性和免疫侮辱。在AKI和CKD中，诊断是 基于血清肌酐和蛋白尿的变化，但这些测试并未区分 各种损伤病因。因此，除了发现肾脏功能的降低外，临床医生通常还有 关于基本病理过程的信息很少。更好地了解细胞和 AKI和CKD患者肾脏的分子模式将为这些疾病提供关键的见解 并将导致新的诊断和治疗方法。近年来，多摩学分析已经 对我们对癌症生物学等几个领域的理解的重大影响，并支持了 识别和开发新疗法。这些相同的技术可以改变我们的 了解AKI和CKD，尤其是在空间分辨率与蛋白质组学相辅相成的时候 转录组细胞分析。尽管肾脏活检通常不在AKI患者中进行 CKD，通过肾脏精密医学项目（KPMP）获得的活检样本提供了宝贵 有机会使用最先进的高维多氨基平台来分析肾脏组织。我们 建议利用互补的空间蛋白和RNA技术来产生综合组织 AKI和CKD的地图集。我们将追求以下特定目的：目标1。生成肾脏蜂窝图 通过表型和功能蛋白表达分析。我们将使用多重离子分析活检 光束成像（MIBI），可通过组织特异性检测单细胞分辨率（250 nm）的40多个蛋白质靶标 空间信息。目标2。通过表型和功能基因生成肾脏形态图 表达分析。我们将使用visious空间转录组学（ST）分析活检，该活检提供了 整个转录组，具有形态学背景。目标3。产生一个集成的细胞和分子蛋白 和基因表达肾图。我们将采用统计和生物信息学方法来整合 AIM 1和2的结果创建了细胞蛋白和转录表达的复合图 肾脏中的特征。为了实现这些目标，我们组建了一个多学科研究团队 包括肾脏科学家，肾脏病理学家，免疫学家和多摩斯系统生物学专家 分析。提出的实验有望根据 肾脏中存在的细胞和分子途径的模式，并支持新颖的鉴定 候选生物标志物和治疗靶标。